Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Executive Summary

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.


Related Content

Ablynx Adds Sanofi To Its List Of Big Pharma Partners
Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes
Shire Aims To Stay On Top In Hemophilia With Novimmune Pact
Touchstone Plays Tough As IP Group Ups Bid To £490m
Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy
Valeant On Track With Debt-Reduction Goals, But Will It Be Enough?
Blood Disorders Overtake Cancer On EMA’s PRIME Scheme
Gardasil Clears Safety Review: No Link To VTE, Mini-Sentinel Study Finds
GSK wins $196m US BARDA contract for anthrax antitoxin raxibacumab
GSK/HGS win US FDA OK for raxibacumab as 1st mAb in anthrax


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts